T cells as sources and targets of TNF: Implications for immunity and autoimmunity

Current Directions in Autoimmunity

Volumn 11, Issue , 2010, Pages 105-118

  Chatzidakis, Ioannis ^a,b   Mamalaki, Clio ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; APOPTOSIS; AUTOIMMUNITY; CELLULAR IMMUNITY; CROHN DISEASE; EFFECTOR CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; THYMUS;

ANIMALS; AUTOIMMUNITY; GRAFT VS HOST DISEASE; HUMANS; MICE; MICE, KNOCKOUT; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; THYMUS GLAND; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84926106111     PISSN: 14222132     EISSN: 16622936     Source Type: Book Series    
DOI: 10.1159/000289200     Document Type: Review

References (105)

1. Ohsawa T, Natori S: Expression of tumor necrosis factor at a specific developmental stage of mouse embryos. Dev Biol 1989;135:459-461.
2. Deman J, Martin MT, Delvenne P, Humblet C, Boniver J, Defresne MP: Analysis by in situ hybridization of cells expressing mRNA for tumor-necrosis factor in the developing thymus of mice. Dev Immunol 1992;2:103-109.
3. Krangel MS, Yssel H, Brocklehurst C, Spits H: A distinct wave of human T cell receptor gamma/delta lymphocytes in the early fetal thymus: evidence for controlled gene rearrangement and cytokine production. J Exp Med 1990;172:847-859.
4. Giroir B P, Brown T, Beutler B: Constitutive synthesis of tumor necrosis factor in the thymus. Proc Natl Acad Sci USA 1992;89:4864-4868.
5. Baseta JG, Stutman O: TNF regulates thymocyte production by apoptosis and proliferation of the triple negative (CD3-CD4-CD8-) subset. J Immunol 2000;165:5621-5630.
6. Zuniga-Pflucker JC, Di J, Lenardo MJ: Requirement for TNF-alpha and IL-1 alpha in fetal thymocyte commitment and differentiation. Science 1995;268: 1906-1909.
7. Samira S, Ferrand C, Peled A, Nagler A, Tovbin Y, Ben-Hur H, Taylor N, Globerson A, Lapidot T: Tumor necrosis factor promotes human T-cell development in nonobese diabetic/severe combined immunodeficient mice. Stem Cells 2004;22:1085-1100.
8. Kato Y, Morikawa A, Sugiyama T, Koide N, Jiang GZ, Takahashi K, Yokochi T: Role of tumor necrosis factor-alpha and glucocorticoid on lipopolysaccha-ride (LPS)-induced apoptosis of thymocytes. FEMS Immunol Med Microbiol 1995;12:195-204.
9. Page DM, Roberts EM, Peschon JJ, Hedrick SM: TNF receptor-deficient mice reveal striking differences between several models of thymocyte negative selection. J Immunol 1998;160:120-133.
10. Page DM: Cutting edge: thymic selection and auto-reactivity are regulated by multiple coreceptors involved in T cell activation. J Immunol 1999;163: 3577-3581.
11. Jondal M, Okret S, McConkey D: Killing of immature CD4+ CD8+ thymocytes in vivo by anti-CD3 or 5′-(N-ethyl)-carboxamide adenosine is blocked by glucocorticoid receptor antagonist RU-486. Eur J Immunol 1993;23:1246-1250.
12. Martin S, Bevan MJ: Antigen-specific and nonspecific deletion of immature cortical thymocytes caused by antigen injection. Eur J Immunol 1997; 27:2726-2736.
13. Kishimoto H, Sprent J: Several different cell surface molecules control negative selection of medullary thymocytes. J Exp Med 1999;190:65-73.
14. Wu AJ, Hua H, Munson SH, McDevitt HO: Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci USA 2002;99:12287-12292.
15. Scheurich P, Thoma B, Ucer U, Pfizenmaier K: Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 1987;138:1786-1790.
16. Yokota S, Geppert TD, Lipsky PE: Enhancement of antigen-and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-alpha. J Immunol 1988;140:531-536.
17. Shalaby MR, Espevik T, Rice GC, Ammann AJ, Figari IS, Ranges GE, Palladino MA Jr: The involvement of human tumor necrosis factors-alpha and-beta in the mixed lymphocyte reaction. J Immunol 1988;141:499-503.
18. Pimentel-Muinos FX, Munoz-Fernandez MA, Fresno M: Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines. J Immunol 1994;152:5714-5722.
19. Aspalter RM, Eibl MM, Wolf HM: Regulation of TCR-mediated T cell activation by TNF-RII. J Leukoc Biol 2003;74:572-582.
20. Banerjee D, Liou HC, Sen R: c-Rel-dependent priming of naive T cells by inflammatory cytokines. Immunity 2005;23:445-458.
21. Kim EY, Priatel JJ, Teh SJ, Teh HS: TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 2006; 176:1026-1035.
22. Kim EY, Teh HS: TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol 2001;167:6812-6820.
23. Kim EY, Teh HS: Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J Immunol 2004;173:4500-4509.
24. Chatzidakis I, Fousteri G, Tsoukatou D, Kollias G, Mamalaki C: An essential role for TNF in modulating thresholds for survival, activation, and tolerance of CD8+ T cells. J Immunol 2007;178:6735-6745.
25. Wiede F, Roomberg A, Cretney E, Lechner A, Fromm P, Wren L, Smyth MJ, Korner H: Age-dependent, polyclonal hyperactivation of T cells is reduced in TNF-negative gld/gld mice. J Leukoc Biol 2009;85:108-116.
26. Cope A P, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO: Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573-1584.
27. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, Feldmann M: Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-760.
28. Isomaki P, Panesar M, Annenkov A, Clark JM, Foxwell BM, Chernajovsky Y, Cope AP: Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface. J Immunol 2001;166:5495-5507.
29. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ: Down-regulation of CD28 expression by TNF-alpha. J Immunol 2001;167:3231-3238.
30. Aspalter RM, Wolf HM, Eibl MM: Chronic TNF-alpha exposure impairs TCR-signaling via TNF-RII but not TNF-RI. Cell Immunol 2005;237:55-67.
31. 2+ influx. J Leukoc Biol 2005;78: 266-278.
32. Sarin A, Conan-Cibotti M, Henkart PA: Cytotoxic effect of TNF and lymphotoxin on T lymphoblasts. J Immunol 1995;155:3716-3718.
33. Aggarwal S, Gollapudi S, Gupta S: Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases. J Immunol 1999;162: 2154-2161.
34. Gupta S, Gollapudi S: TNF-alpha-induced apopto-sis in human naive and memory CD8+ T cells in aged humans. Exp Gerontol 2006;41:69-77.
35. Reich A, Korner H, Sedgwick JD, Pircher H: Immune down-regulation and peripheral deletion of CD8 T cells does not require TNF receptor-ligand interactions nor CD95 (Fas, APO-1). Eur J Immunol 2000;30:678-682.
36. Nguyen LT, McKall-Faienza K, Zakarian A, Speiser DE, Mak T W, Ohashi PS: TNF receptor 1 (TNFR1) and CD95 are not required for T cell deletion after virus infection but contribute to peptide-induced deletion under limited conditions. Eur J Immunol 2000;30:683-688.
37. Sytwu HK, Liblau RS, McDevitt HO: The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 1996;5:17-30.
38. Murray DA, Crispe IN. TNF-alpha controls intra-hepatic T cell apoptosis and peripheral T cell numbers: J Immunol 2004;173:2402-2409.
39. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995;377: 348-351.
40. Teh H-S, Seebaran A, Teh S-J: TNF receptor 2-defi-cient CD8 T cells are resistant to Fas/Fas ligand-induced cell death. J Immunol 2000;165:4814-4821.
41. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappa B. Science 1996;274:787-789.
42. Speiser DE, Sebzda E, Ohteki T, Bachmann MF, Pfeffer K, Mak T W, Ohashi PS: Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol 1996;26:3055-3060.
43. de Oliveira Pinto LM, Garcia S, Lecoeur H, Rapp C, Gougeon M-L: Increased sensitivity of T lymphocytes to tumor necrosis factor receptor 1 (TNFR1)-and TNFR2-mediated apoptosis in HIV infection: relation to expression of Bcl-2 and active caspase-8 and caspase-3. Blood 2002;99:1666-1675.
44. Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL: Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 ago-nism. Proc Natl Acad Sci 2008;105:13644-13649.
45. Zhang H-G, Liu C, Su K, Yu S, Zhang L, Zhang S, Wang J, Cao X, Grizzle W, Kimberly RP: A membrane form of TNF-alpha presented by exosomes delays T cell activation-induced cell death. J Immunol 2006;176:7385-7393.
46. Marino M W, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, Jungbluth A, Wada H, Moore M, Williamson B, Basu S, Old LJ: Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997;94:8093-8098.
47. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G: Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996;184:1397-1411.
48. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW: Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endo-toxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-467.
49. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H: Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated tox-icity but highly susceptible to infection by Listeria monocytogenes. Nature 1993;364:798-802.
50. Ehlers S, Benini J, Kutsch S, Endres R, Rietschel ET, Pfeffer K: Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect Immun 1999;67:3571-3579.
51. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak T W, Bloom BR: Tumor necrosis factor-alpha is required in the protective immune response against Myco-bacterium tuberculosis in mice. Immunity 1995;2: 561-572.
52. Mohan V P, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, Tsai MM, Flynn JL, Chan J: Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69: 1847-1855.
53. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285.
54. Bradley JR: TNF-mediated inflammatory disease. J Pathol 2008;214:149-160.
55. Brehm MA, Daniels KA, Welsh RM: Rapid production of TNF-alpha following TCR engagement of naive CD8 T cells. J Immunol 2005;175:5043-5049.
56. Saunders BM, Briscoe H, Britton WJ: T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. Clin Exp Immunol 2004;137: 279-287.
57. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, Britton WJ: Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 2005;174:4852-4859.
58. Cowley SC, Sedgwick JD, Elkins KL: Differential requirements by CD4+ and CD8+ T cells for soluble and membrane TNF in control of Francisella tularensis live vaccine strain intramacrophage growth. J Immunol 2007;179:7709-7719.
59. Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, Mak T W, Ohashi PS: TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 2007;117:3833-3845.
60. Singh A, Wuthrich M, Klein B, Suresh M: Indirect regulation of CD4 T-cell responses by tumor necrosis factor receptors in an acute viral infection. J Virol 2007;81:6502-6512.
61. Singh A, Suresh M: A role for TNF in limiting the duration of CTL effector phase and magnitude of CD8 T cell memory. J Leukoc Biol 2007;82:1201-1211.
62. Kafrouni MI, Brown GR, Thiele DL: The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection. J Leukoc Biol 2003;74:564-571.
63. Bitsaktsis C, Winslow G: Fatal recall responses mediated by CD8 T cells during intracellular bacterial challenge infection. J Immunol 2006;177:4644-4651.
64. Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Shakhov AN, Murakami T, Drutskaya LN, Forster I, Clausen BE, Tessarollo L, Ryffel B, Kuprash DV, Nedospasov SA: Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/neutrophils: protective and deleterious effects. Immunity 2005;22:93-104.
65. Togbe D, Grivennikov SI, Noulin N, Couillin I, Maillet I, Jacobs M, Maret M, Fick L, Nedospasov SA, Quesniaux VF, Schnyder B, Schnyder-Candrian S: T cell-derived TNF down-regulates acute airway response to endotoxin. Eur J Immunol 2007;37:768-779.
66. Ratner A, Clark WR: Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis. J Immunol 1993;150:4303-4314.
67. Gonthier M, Llobera R, Arnaud J, Rubin B: Self-reactive T cell receptor-reactive CD8+ T cells inhibit T cell lymphoma growth in vivo. J Immunol 2004;173:7062-7069.
68. Perret R, Ronchese F: Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo. Eur J Immunol 2008;38: 2886-2895.
69. Prevost-Blondel A, Roth E, Rosenthal FM, Pircher H: Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 2000;164:3645-3651.
70. Poehlein CH, Hu HM, Yamada J, Assmann I, Alvord WG, Urba WJ, Fox BA: TNF plays an essential role in tumor regression after adoptive transfer of perfo-rin/IFN-gamma double knockout effector T cells. J Immunol 2003;170:2004-2013.
71. Dace DS, Chen P W, Niederkorn JY: CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism. J Immunol 2007;178: 6115-6122.
72. Hill GR, Teshima T, Rebel VI, Krijanovski OI, Cooke KR, Brinson YS, Ferrara JL: The p55 TNF-alpha receptor plays a critical role in T cell alloreac-tivity. J Immunol 2000;164:656-663.
73. Brown GR, Lee E, Thiele DL: TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J→C57BL/6J × bm12)F1 mice. J Immunol 2002;168:3065-3071.
74. Brown GR, Lee EL, Thiele DL: TNF enhances CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease by IL-12-independent mechanisms. J Immunol 2003;170: 5082-5088.
75. El-Hayek JM, Rogers TE, Brown GR: The role of TNF in hepatic histopathological manifestations and hepatic CD8+ T cell alloresponses in murine MHC class I disparate GVHD. J Leukoc Biol 2005; 78:1001-1007.
76. Borsotti C, Franklin AR, Lu SX, Kim TD, Smith OM, Suh D, King CG, Chow A, Liu C, Alpdogan O, van den Brink MR: Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood 2007;110:783-786.
77. Anderson MS, Bluestone JA: The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005;23:447-485.
78. Cantor J, Haskins K: Effector function of diabeto-genic CD4 Th1 T cell clones: a central role for TNF-alpha. J Immunol 2005;175:7738-7745.
79. Lee LF, Lih CJ, Huang CJ, Cao T, Cohen SN, McDevitt HO: Genomic expression profiling of TNF-alpha-treated BDC2.5 diabetogenic CD4+ T cells. Proc Natl Acad Sci USA 2008;105:10107-10112.
80. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H: Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci USA 1990;87:968-972.
81. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, McDevitt HO: Effect of tumor necrosis factor alpha on insulin-dependent diabetes mel-litus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994;180:995-1004.
82. Green EA, Eynon EE, Flavell RA: Local expression of TNFalpha in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 1998;9:733-743.
83. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, Flavell RA: Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996;184:1963-1974.
84. Guerder S, Picarella DE, Linsley PS, Flavell RA: Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoim-munity in transgenic mice. Proc Natl Acad Sci USA 1994;91:5138-5142.
85. Herrera PL, Harlan DM, Vassalli P: A mouse CD8 T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways: possible role of membrane TNF. Proc Natl Acad Sci USA 2000;97:279-284.
86. Green EA, Flavell RA: The temporal importance of TNFalpha expression in the development of diabetes. Immunity 2000;12:459-469.
87. Ostor AJ: Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. Clin Rheumatol 2008;27:1343-1353.
88. Isaacs JD: Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology (Oxford) 2008;47:1461-1468.
89. Probert L, Keffer J, Corbella P, Cazlaris H, Patsavoudi E, Stephens S, Kaslaris E, Kioussis D, Kollias G: Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes. J Immunol 1993;151: 1894-1906.
90. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10:387-398.
91. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277-285.
92. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO: Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008;205:2491-2497.
93. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN: Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:38-47.
94. Campbell IK, O'Donnell K, Lawlor KE, Wicks IP: Severe inflammatory arthritis and lymphadenopa-thy in the absence of TNF. J Clin Invest 2001;107: 1519-1527.
95. Kruglov AA, Kuchmiy A, Grivennikov SI, Tumanov AV, Kuprash DV, Nedospasov SA: Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev 2008;19:231-244.
96. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J: A pathogenic role for myelin-specific CD8+ T cells in a model for multiple sclerosis. J Exp Med 2001;194:669-676.
97. Kassiotis G, Kollias G: Uncoupling the proinflam-matory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001; 193:427-434.
98. Probert L, Eugster HP, Akassoglou K, Bauer J, Frei K, Lassmann H, Fontana A: TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 2000;123:2005-2019.
99. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CC: TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4:78-83.
100. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T: Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009;45:55-57.
101. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-1785.
102. Ricciardelli I, Lindley KJ, Londei M, Quaratino S: Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology 2008;125: 178-183.
103. Hueber AJ, McInnes IB: Immune regulation in psoriasis and psoriatic arthritis - recent developments. Immunol Lett 2007;114:59-65.
104. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-2729.
105. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, Fuentes-Duculan J, Novitskaya I, Khatcherian A, Bluth MJ, Lowes MA, Krueger JG: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-3194.